Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11530218 Spiro compounds as inhibitors of KRAS

Patent 11530218 was granted and assigned to Incyte on December, 2022 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent attributes

Patent Applicant

Current Assignee

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

Date of Patent

December 20, 2022

Patent Application Number

17153065

Date Filed

January 20, 2021

Patent Citations

US Patent 10544138 Tricyclic kinase inhibitors of MELK and methods of use

US Patent 10039753 Imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives as LRRK2 inhibitors

US Patent 10493071 Use of pyrroloquinoline compounds to kill clinically latent microorganisms

US Patent 11053240 2-amino-quinoline derivatives

Patent Primary Examiner

Jeffrey H Murray

CPC Code

Disclosed are spirocyclic compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and treating cancer, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11530218 Spiro compounds as inhibitors of KRAS

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool